TissueTech to Commence Study on Facet Joint Osteoarthritis Pain

TissueTech, parent company to Amniox Medical, received FDA clearance to commence a dosing study using its Investigational New Drug TTAX03 to treat facet joint pain resulting from osteoarthritis (OA). FDA clearance of this application represents one of the first steps in commercializing TTAX03-FJ as a biologic.

This Phase I randomized,...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us